Ursus S.A. (URS) Financials Nov 17, 2014, 12:00

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
Ursus S.A. (URS) Financials Nov 17, 2014, 12:00 a.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Ursus S.A.


Fiscal year is January-December. All values PLN millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 107.15M 122.83M 172.36M 227.37M 168.04M
Cost of Goods Sold (COGS) incl. D&A 91.77M 106.09M 146.66M 192.55M 151.7M
COGS excluding D&A 86.43M 100.72M 141.21M 186.49M 145.1M
Depreciation & Amortization Expense 5.34M 5.38M 5.45M 6.05M 6.6M
Depreciation 4.58M - - 4.81M -
Amortization of Intangibles 757,000 - - 1.24M -
Gross Income 15.38M 16.74M 25.7M 34.83M 16.34M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 15.62M 20.96M 24.85M 32.23M 35.42M
Research & Development 0 0 - - -
Other SG&A 15.62M 20.96M 24.85M 32.23M 35.42M
Other Operating Expense 1.22M 559,000 216,000 570,000 1.7M
Unusual Expense (302,000) 130,000 (800,000) (3.85M) 206,000
EBIT after Unusual Expense 302,000 (130,000) 800,000 3.85M (206,000)
Non Operating Income/Expense 2.65M 7.75M 372,000 773,000 57,000
Non-Operating Interest Income 19,000 250,000 1.67M 575,000 38,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 1.35M 1.63M 2.49M 2.72M 4.1M
Gross Interest Expense 1.35M 1.63M 2.49M 2.72M 4.1M
Interest Capitalized - 0 0 0 0
Pretax Income 167,000 1.46M 980,000 4.5M (24.98M)
Income Tax 491,000 785,000 (338,000) 702,000 (2.54M)
Income Tax - Current Domestic - 27,000 0 0 0
Income Tax - Current Foreign - 0 - 0 0
Income Tax - Deferred Domestic - 758,000 (338,000) 702,000 (2.54M)
Income Tax - Deferred Foreign - 0 - - -
Income Tax Credits - 0 - 0 0
Equity in Affiliates (451,000) (42,000) 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (775,000) 635,000 1.32M 3.8M (22.44M)
Minority Interest Expense 0 226,000 107,000 (1.81M) 33,000
Net Income (775,000) 409,000 1.21M 5.61M (22.47M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (775,000) 409,000 1.21M 5.61M (22.47M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (775,000) 409,000 1.21M 5.61M (22.47M)
EPS (Basic) (0.03) 0.02 0.05 0.25 (0.86)
Basic Shares Outstanding 24.03M 24.03M 24.03M 22.18M 26.18M
EPS (Diluted) (0.03) 0.02 0.05 0.21 (0.86)
Diluted Shares Outstanding 24.03M 24.03M 24.03M 26.18M 26.18M
EBITDA 3.88M 601,000 6.08M 8.08M (14.17M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 2

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Findings on gMG Treatments by UCB at AANEM 2024

Updated Category News Views 127

UCB Highlights Innovations in Generalized Myasthenia Gravis Treatments at AANEM 2024 UCB, a prominent global biopharmaceutical company, is gearing up to present its latest findings in the management of generalized myasthenia gravis (gMG) at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) meeting. The event, which will also feature...

Continue Reading
Lysander Funds Shares New Distributions Estimates for ETFs

Updated Category News Views 131

Lysander Funds Shares New Distributions Estimates Lysander Funds Limited recently made an announcement about the anticipated cash distributions for December 2024 for their exchange-traded funds (ETFs). The focus is on three notable ETFs: Lysander-Slater Preferred Share ActivETF, Lysander-Canso Corporate Treasury ActivETF, and Lysander-Canso Floating Rate ActivETF. Each of...

Continue Reading
Empowering Girls: Pace Center's Initiatives for Growth

Updated Category News Views 350

Introduction to the Capital Campaign Pace Center for Girls Hillsborough is excited to announce its capital campaign aimed at expanding its capacity and enhancing the support provided to girls in the community. Through dedicated efforts such as education, counseling, and training, this campaign signifies a crucial step towards bettering the future for girls in Hillsborough...

Continue Reading
Bank of America Sees Growth in Loans, Deposits Amid Profit Rise

Updated Category News Views 284

Bank of America Reports Increased Earnings and Efficiency Bank of America Corp (NASDAQ: BAC) has announced strong financial results for the second quarter, showcasing impressive growth in loans, deposits, and overall profitability. The bank reported a net income of $7.1 billion, a slight increase from $6.9 billion the previous year, along with an earnings per share (EPS)...

Continue Reading
Investigating Manitex International: A Closer Look at MNTX

Updated Category News Views 72

Examining Fair Treatment for Manitex International Shareholders Ademi LLP has launched an investigation into Manitex International, Inc. (NASDAQ: MNTX) due to concerns about possible breaches of fiduciary duty related to its recent transaction with Tadano. This investigation raises important questions about whether shareholders are being treated fairly in the financial...

Continue Reading